Overview

Phase II Study of BI 2536 in Prostate Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A study to investigate the activity of BI 2536 in Prostate Cancer
Phase:
Phase 2
Details
Lead Sponsor:
Boehringer Ingelheim